A drug originally used to boost the immune system is showing promise as a potential new treatment for lupus, joint Monash University and Peking University research published today shows. Lupus is an autoimmune disease, where the immune system attacks the body’s own organs and tissues.
An international team of scientists from Australia and China have, for the first time, shown in a study published in Nature Medicine, that a natural immune system protein called IL-2 can help restore balance to the overactive immune system of lupus patients. The drug could soon be rolled out for clinical trials in lupus treatment.
Monash Biomedicine Discovery Institute researcher, Dr Di Yu and Professor Zhanguo Li from Peking University People’s Hospital in China co-led the study.
Dr Yu said he hoped the drug could be approved as a lupus treatment within a handful of years.
“This drug, which can help the immune system fight against cancer, was approved in the 1990s but is not commonly used now. We’re now using this drug for a different purpose, based on our new knowledge of the immune system,” Dr Yu said.
“The amount we tested for treating lupus is much less than the dose used in treating cancers. We observed the treatment was safe and showed promising results, so there’s reason to believe formal trials could begin almost immediately,” he said.
Dr Yu said lupus could be a serious disease, and that it hadn’t been able to be treated in a very satisfactory way in the past.
IL-2 is a protein that regulates the activity of white blood cells, which are an important part of the immune system that protect the body against infections. In cancer therapy, patients are given large doses of IL-2 to stimulate their immune system but, paradoxically, the low dose IL-2 given to lupus sufferers in this study actually supressed the overactive part of their immune system that attacks their body. The research also showed the “self-checking” part of the immune system that prevents an overactive immune response, called regulatory T cells, increased after IL-2 treatment.
Professor Eric Morand, fellow Monash University researcher on the study and founder of the Asia Pacific Lupus Collaboration, said that in this study, IL-2 was given to people whose lupus wasn’t responding well to standard treatments.
“The real promise of this treatment is that it calms the hyperactive immune system through multiple mechanisms, which is very important as this new therapy may be effective for many patients,” Professor Morand said.
”As the drug has been on the market for some time for other diseases, it can be rapidly put into formal trials for lupus treatment right away.”
Learn more: Promising new treatment for lupus on the horizon
The Latest on: Lupus
via Google News
The Latest on: Lupus
- Selena Gomez Opens Up About Her Battle Against Lupuson November 11, 2019 at 8:09 pm
According to E! News, in a recent interview with Giving Back Generation, the 27-year-old singer explained how suffering from Lupus gave her nightmares and contributed to issues like mental and ...
- New data shows benefit of lupus drugon November 11, 2019 at 4:09 pm
MANHASSET, N.Y., Nov. 11, 2019 /PRNewswire/ -- The Feinstein Institutes for Medical Research Professor Richard Furie, MD, will publish and present data describing the clinical benefit of anifrolumab ...
- Selena Gomez Says People Were ''Attacking'' Her For Gaining Weight Amid Lupus Battleon November 11, 2019 at 4:08 pm
She adds that this contributed to her decision to briefly leave social media. Since then, she's returned to the app but she says that nowadays she hardly looks at her timeline. Selena says, "I'm very ...
- Male patients with lupus often have more severe disease, receive little supporton November 11, 2019 at 2:56 pm
A national survey of male patients with lupus finds the illness has a significant impact on their physical and emotional health, yet they often do not receive support that could help them cope.
- Lupus flare-ups could be linked to environmental factorson November 11, 2019 at 1:09 pm
Researchers have found that alteration in the environment and atomospheric factors could be associated with organ specific flare-ups of lupus among patients diagnosed with Systemic Lupus Erethematosus ...
- AstraZeneca succeeds in treating late-stage lupus in new studyon November 11, 2019 at 9:23 am
The drugmaker AstraZeneca said on Monday its experimental treatment significantly reduced disease activity in patients with the autoimmune disorder lupus in a late-stage study.
- B-Cell Depleting Agent Shows Promise in Lupus Nephritison November 11, 2019 at 8:37 am
WASHINGTON -- Patients with proliferative lupus nephritis appeared to benefit from treatment with obinutuzumab (Gazyva) plus a steroid, according to a phase II trial presented here. In the NOBIILITY ...
- AstraZeneca succeeds in treating lupus in late-stage studyon November 11, 2019 at 8:15 am
(Reuters) - AstraZeneca Plc said on Monday its experimental treatment significantly reduced disease activity in patients with autoimmune disorder lupus, in a late-stage study. The results pit the ...
- Lupus Foundation of America Georgia Chapter Night of Hope Galaon November 11, 2019 at 7:28 am
Lupus is an unpredictable and potentially fatal autoimmune disease that affects 55,000 Georgians, mostly women aged 18-45, but also men, children, and women of all ages. Ninety percent of every dollar ...
- Sudden weather changes may trigger organ-specific lupus flareson November 11, 2019 at 3:22 am
ATLANTA — Atmospheric changes and associated environmental stressors within 10 days of a clinic visit were linked to organ-specific lupus flares among patients with systemic lupus erythematosus, ...
via Bing News